This is the authors' abstract. We don't add key points for this paper.
Supplementary Figure S3. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with second or later line osimertinib (T790M+). The point estimate for median progression free survival associated with each mutation is listed to the right of the figure legend.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Grant et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: